Bookmark and Share

Simeon I. Taylor M.D., Ph.D.

Academic Title: Professor
Primary Appointment: Medicine
staylor2@medicine.umaryland.edu
Location: MSTF, 357B
Phone: 410-706-6439
 

Personal History:

Dr. Simeon Taylor received a B.A. (Chemistry) from Harvard College in 1969, followed by Ph.D. and M.D. degrees from Harvard Medical School in 1974 and 1976, respectively. He completed clinical training in the specialty of Internal Medicine and sub-specialty of Endocrinology & Metabolism at Massachusetts General Hospital (1976-1979) and National Institutes of Health (1979-1981). He worked in the Intramural Research Program of NIDDK (1979-2000), where he occupied positions of increasing responsibility, including Chief of the Diabetes Branch (1989-2000). His work at NIDDK was recognized by the Outstanding Service Award, Unites States Public Health Service (1990) and the Outstanding Scientific Achievement Award of the American Diabetes Association (1992). In addition, he served as Director of the NIH Inter-Institute Clinical Training Program in Endocrinology & Metabolism (1995-1998).

He moved to the pharmaceutical industry in 2000: first at Eli Lilly (2000-2002) where he was a Lilly Research Fellow in Endocrine Research and later at Bristol-Myers Squibb where he served as Vice President Cardiovascular & Metabolic Disease Research (2002-2010) and Vice President Research & Scientific Affairs (2010-2013). During his time at Bristol-Myers Squibb, he made substantial contributions to R&D leading to four approved drugs: saxagliptin, dapagliflozin, apixaban, and metreleptin.

He joined the faculty at the University of Maryland School of Medicine in 2013, first as an Adjunct Professor of Medicine (2013-2015) and currently as a Professor of Medicine. In addition, he serves as Director of the Mid-Atlantic Nutrition Obesity Research Center.

Research Interests:

Dr. Taylor has two principal research interests: (1) the genetics of cardiometabolic disease in the Old Order Amish; and (2) precision medicine and pharmacogenomics related to anti-diabetic therapies.


Clinical Specialty:

Dr. Taylor specializes in endocrinology, diabetes, and metabolic disease.


Grants and Contracts:

  • 2P30DK072488 Mid-Atlantic Nutrition Obesity Research Center PI: Simeon I. Taylor September, 2010 - August, 2015

Publications:

  1. Taylor SI, Grunberger G, Marcus-Samuels B, Underhill LH, Dons RF, Ryan J, Roddam RF, Rupe CE, Gorden P (1982) Hypoglycemia associated with antibodies to the insulin receptor. N Engl J Med, 307: 1422-1426. PMID: 7133096.
  2. Rees-Jones RW, Taylor SI (1985) An endogenous substrate for the insulin receptor-associated tyrosine kinase. J Biol Chem 260: 4461-4467. PMID: 3884611
  3. Perrotti N, Accili D, Marcus-Samuels B, Rees-Jones RW., Taylor SI (1987) Insulin stimulates phosphorylation of a 120-kDa glycoprotein substrate (pp120) for the receptor-associated protein kinase in intact H-35 hepatoma cells. Proc Natl Acad Sci USA 84: 3137-3140. PMID: 3033636
  4. Gherzi R, Russell DS, Taylor SI, Rosen OM (1987) Reevaluation of the evidence that an antibody to the insulin receptor is insulinmimetic without activating the protein tyrosine kinase activity of the receptor. J Biol Chem 262: 16900-16905. PMID: 3680277
  5. Margolis RN, Taylor SI, Seminara D, Hubbard AL (1988) Identification of pp120, an endogenous substrate for the hepatocyte insulin receptor tyrosine kinase, as an integral membrane glycoprotein of the bile canalicular domain. Proc Natl Acad Sci USA 85: 7256-7259. PMID: 2845403.
  6. Kadowaki T, Bevins CL, Cama A, Ojamaa K, Marcus-Samuels B, Kadowaki H, Beitz L, McKeon C, Taylor SI (1988) Two mutant alleles of the insulin receptor gene in a patient with extreme insulin resistance. Science, 240: 787-790. PMID: 2834824.
  7. Accili D, Frapier C, Mosthaf L, McKeon C, Elbein S, Permutt MA, Ramos E, Lander E, Ullrich A, Taylor SI (1989) A mutation in the insulin receptor gene that impairs transport of the receptor to the plasma membrane and causes insulin resistant diabetes. EMBO J, 8:2509-2517. PMID: 3573522.
  8. Kadowaki T, Kadowaki H, Taylor SI (1990) A nonsense mutation causing decreased levels of insulin receptor mRNA: Detection by a simplified technique for direct sequencing of genomic DNA amplified by polymerase chain reaction, Proc Natl Acad Sci USA, 87:658-662. PMID: 2300553.
  9. Hurley, DM Accili, D, Stratakis CA, Karl M, Vamvakopoulos N, Rorer E, Constantine K, Taylor SI, Chrousos, GP (1991) Point mutation causing a single amino acid substitution in the hormone binding domain of the glucocorticoid receptor in familial glucocorticoid resistance. J Clin Invest 87: 680-686. PMID: 1704018
  10. Taylor SI (1992) 1992 Lilly Lecture. Molecular mechanisms of insulin resistance: lessons from patients with mutations in the insulin receptor gene. Diabetes, 41: 1473-1490. PMID: 1327927.
  11. Wertheimer E, Lu SP, Backeljauw PF, Davenport ML, Taylor SI (1993) Homozygous deletion of the human insulin receptor gene. Nature Genetics, 5:71-73. PMID: 7693131.
  12. Najjar SM, Accili, D, Philippe N, Jernberg J, Margolis R, Taylor SI (1993) pp120/ecto-ATPase, an endogenous substrate of the insulin receptor tyrosine kinase, is expressed as two variably spliced isoforms. J Biol Chem 268: 1201-1206. PMID: 8380406
  13. Quon MJ, Chen H, Ing BL, Liu ML, Zarnowski MJ, Yonezawa K, Kasuga M, Cushman SW, Taylor SI (1995) Roles of 1-phosphatidylinositol 3-kinase and ras in regulating translocation of GLUT4 in transfected rat adipose cells. Mol Cell Biol 15: 5403-5411. PMID: 7565691.
  14. Accili D, Drago J, Lee EJ, Johnson MD, Cool MH, Salvatore P, Asico LD, Jose PA, Taylor SI, Westphal H (1996) Early neonatal death in mice homozygous for a null allele of the insulin receptor gene. Nat Genet 12: 106-109, 1996. PMID: 8528241
  15. Arioglu E, Duncan-Morin J, Sebring N, Rother KI, Cochran C, Herion D, Kleiner D, Reynolds J, Premkumar A, Calis K, Gottlieb N, Lieberman J, Skarulis M, Sumner AE, Reitman ML, Taylor SI (2000) Efficacy of troglitazone in treatment of lipodystrophy syndromes: weighing the risks and benefits. Ann Intern Med, 133: 263-274. PMID: 10929166.
  16. Arioglu-Oral E, Simha V, Ruiz E, Sebring N, Andewelt A, Premkumar A, Snell P, Wagner A, DePaoli A, Reitman ML, Taylor SI, Gorden P, Garg A (2002) Efficacy and safety of leptin replacement in treatment of lipodystrophy. N Engl J Med, 346: 570-578. PMID: 11856796.
  17. Petersen KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C, Cline GW, DePaoli AM, Taylor SI, Gorden P, Shulman GI (2002) Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest, 109: 1345-1350. PMID: 12021250.
  18. Agarwal AK, Arioglu E, de Almeida S, Akkoc N, Taylor SI, Bowcock AM, Barnes RI, Garg A (2002) AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. Nature Genetics, 31: 21-23. PMID: 11967537.
  19. Tozzo E, Ponticiello R, Swartz J, Farrelly D, Zebo R, Welzel G, Egan D, Kunselman L, Peters A, Gu L, French M, Chen S, Devasthale P, Janovitz E, Staal A, Harrity T, Belder R, Cheng PT, Whaley J, Taylor S, Hariharan N (2007) The dual peroxisome proliferator-activated receptor alpha/gamma activator muraglitazar prevents the natural progression of diabetes in db/db mice. J Pharmacol Exp Ther 321: 107-115. PMID: 17259449.
  20. Taylor SI, Blau JE, Rother KI (2015) Possible adverse effects of SGLT2-inhibitors on bone. Lancet Diabetes & Endocrinology 3: 8-10. PMID: 25523498.